92 related articles for article (PubMed ID: 3551350)
21. Rapid estimation of total body clearance of theophylline in patients receiving intravenous aminophylline infusion.
Lau AH; O'Connor T; Lam G; Lui CY; Al-Bazzaz FJ; Chiou WL
Int J Clin Pharmacol Ther Toxicol; 1986 Jan; 24(1):12-5. PubMed ID: 3957483
[TBL] [Abstract][Full Text] [Related]
22. Long-term therapy with sustained-release theophylline.
Myhre KI; Arnulf V; Walstad RA
Pharmatherapeutica; 1985; 4(2):92-7. PubMed ID: 3903782
[TBL] [Abstract][Full Text] [Related]
23. Serum theophylline and ventilatory function in chronic obstructive lung disease. Comparison between two slow-release formulations of theophylline.
Tantucci C; Grassi V; Verdecchia P; Cornelli U; Sorbini CA
Int J Clin Pharmacol Ther Toxicol; 1985 Oct; 23(10):560-4. PubMed ID: 3905630
[TBL] [Abstract][Full Text] [Related]
24. [Results of a serum concentration-oriented dosage of a theophylline depot preparation in ambulatory patients with chronic obstructive lung disease].
Harder S; Staib AH; Stauder J
Prax Klin Pneumol; 1985 Jun; 39(6):193-6. PubMed ID: 4022931
[No Abstract] [Full Text] [Related]
25. Oral doxophylline in patients with chronic obstructive pulmonary disease.
Villani F; De Maria P; Ronchi E; Galimberti M
Int J Clin Pharmacol Ther; 1997 Mar; 35(3):107-11. PubMed ID: 9088999
[TBL] [Abstract][Full Text] [Related]
26. Slow release theophylline in patients with airways obstruction with particular reference to the effects of food upon serum levels.
Thompson PJ; Kemp MW; McAllister WA; Turner-Warwick M
Br J Dis Chest; 1983 Jul; 77(3):293-8. PubMed ID: 6351891
[TBL] [Abstract][Full Text] [Related]
27. [Optimizing therapy with theophylline preparations in obstructive ventilation disorders. 3. Prediction of theophylline clearance with a simple pharmacokinetic method and comparison of bioavailability of various theophylline retard preparations].
Ranke C; Schmidt G; Oellerich M; Sybrecht GW
Prax Klin Pneumol; 1983 Mar; 37(3):99-108. PubMed ID: 6856564
[No Abstract] [Full Text] [Related]
28. [Comparison of 2 theophylline delayed-action preparations of different galenic forms].
Hirsch H
Wien Med Wochenschr; 1983 Aug; 133(15-16):403-8. PubMed ID: 6636797
[TBL] [Abstract][Full Text] [Related]
29. [Pharmacokinetic and therapeutic monitoring in the development of theophylline-retard preparations].
Iwainsky H; Wilke A; Weide W; Schäfer K
Pharmazie; 1987 Apr; 42(4):242-4. PubMed ID: 3615555
[TBL] [Abstract][Full Text] [Related]
30. [Application of theophylline as an inhalant (author's transl)].
Kandt D; Sehrt I; Iwainsky H
Z Erkr Atmungsorgane; 1981 May; 157(2):152-9. PubMed ID: 7314689
[TBL] [Abstract][Full Text] [Related]
31. [Serum theophylline steady-state levels: comparative study of 2 retard preparations].
Kaukel E; Koppermann G
Prax Klin Pneumol; 1983 Mar; 37(3):109-12. PubMed ID: 6856560
[No Abstract] [Full Text] [Related]
32. [Double-blind crossover study on the long-term effects of aminophylline retard tablets on the use of salbutamol aerosol spray].
Brändli O; Langloh P
Schweiz Rundsch Med Prax; 1982 Oct; 71(40):1553-8. PubMed ID: 6757909
[No Abstract] [Full Text] [Related]
33. Phyllocontin in chronic airflow obstruction.
Dunn A; Hoffman N; Wilson RS
Br J Clin Pract; 1984 Feb; 38(2):63-5. PubMed ID: 6367798
[No Abstract] [Full Text] [Related]
34. Controversies in pulmonary medicine. Aminophylline should be administered for all acute exacerbations of COPD.
Ziment I; Niewoehner DE
Am Rev Respir Dis; 1988 Oct; 138(4):1070. PubMed ID: 3202440
[No Abstract] [Full Text] [Related]
35. [Obstructive airway diseases. Basic therapy with pure theophylline in retard form].
Pollert I
Fortschr Med; 1982 Mar; 100(12):547-50. PubMed ID: 7042500
[No Abstract] [Full Text] [Related]
36. Serum theophylline levels with oral sustained release theophylline after transfer from intravenous aminophylline in patients with chronic lung disease.
Silins RA; Butcher MA; Marlin GE
Br J Clin Pharmacol; 1984 Oct; 18(4):645-7. PubMed ID: 6487509
[No Abstract] [Full Text] [Related]
37. Comparison of aminophylline and theophylline sustained-release formulations by their bioavailability and steady-state serum levels.
Steinijans VW; Zech K; Fischer R
Int J Clin Pharmacol Ther Toxicol; 1983 Dec; 21(12):624-30. PubMed ID: 6668100
[TBL] [Abstract][Full Text] [Related]
38. Short-acting versus a long-acting preparation of theophylline ('Xantivent') in the treatment of reversible bronchospasm.
Andrasch R; Schmitz-Schumann M
Pharmatherapeutica; 1984; 3(10):668-77. PubMed ID: 6463066
[TBL] [Abstract][Full Text] [Related]
39. A controlled study of slow-release theophylline and aminophylline in patients with chronic bronchitis.
Jenkins PF; White JP; Jariwalla AJ; Anderson G; Campbell IA
Br J Dis Chest; 1982 Jan; 76(1):57-60. PubMed ID: 7037034
[TBL] [Abstract][Full Text] [Related]
40. The combined effect of theophylline and terbutaline in patients with chronic obstructive airway diseases.
Lamont H; van der Straeten M; Pauwels R; Moerman E; Bogaert M
Eur J Respir Dis; 1982 Jan; 63(1):13-22. PubMed ID: 7040097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
